Fuda Cancer Hospital
Fuda Cancer Hospital
Қытай, Гуаңджоу
| Қытай | Түркия | Австрия | |
| Өкпені алып тастау | бастап $24,000 | бастап $10,872 | бастап $50,000 |
| Өкпе рагын емдеу үшін операция | бастап $24,500 | бастап $17,000 | бастап $42,000 |
| Тік ішек қатерлі ісігінде сәулелік терапия | бастап $11,500 | бастап $7,000 | бастап $12,000 |
| Сүт безі рагында химиотерапия | бастап $14,800 | бастап $1,200 | бастап $15,000 |
| Стереотактикалық радиохирургия | бастап $8,500 | бастап $4,500 | бастап $17,000 |
Сіз Bookimed қызметтері үшін төлемейсіз. өкпе рагының 4 cатысының емдеудің бағалары клиниканың баға тізіміне сәйкес келеді. Сіз жеткенде тікелей клиникада төлейсіз. Бөліктермен төлеу қолжетімді.
Bookimed Сіздің қауіпсіздігіңізді қамтамасыз етеді. Біз тек өкпе рагының 4 cатысының жүргізу үшін жоғары халықаралық стандарттарға сәйкес келетін клиникалармен ғана жұмыс істейміз. Олардың бүкіл әлем бойынша халықаралық науқастарға қызмет көрсету үшін қажетті лицензиялары бар.
Bookimed тегін көмек және қолдау ұсынады. Жеке медициналық координатор сапарға дейін, кезінде және кейін Сізбен байланыста. өкпе рагының 4 cатысының емдеу кезінде Сіз басқа елде жалғыз қалмайсыз.
Dr. Liuying leads the Oncology Ward at Jinshazhou Hospital, Guangzhou University of Chinese Medicine. Clinical focus includes hepatocellular carcinoma, cholangiocarcinoma, and lung and colorectal cancers. Dr. Liuying has special expertise in melanoma and melanoma liver metastasis. Interventional skills include MWA, RFA, cryoablation, and radioactive seed implantation for non-vascular, minimally invasive tumor ablation.
Research: participated in two Guangdong Provincial science and technology projects. Contributed to the 2014 Expert Consensus for Thermal Ablation of Primary and Metastatic Lung Tumors. Published in the Chinese Journal of Lung Cancer. Compiled Selected Cases of Microwave Ablation for Lung Tumors and Selected Cases of Microwave Ablation for Liver Tumors.
Appointments: Standing Committee Member, Youth Committee of Intra-Tumor Brachytherapy Medicine, China Medical Education Association. Standing Committee Member, Minimally Invasive Interventional Medicine Professional Committee, Guangdong Primary Medical Association.
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.
China offers advanced stage 4 lung cancer therapies including mutation-specific tyrosine kinase inhibitors and homegrown immunotherapies. Patients access next-generation drugs like Sunvozertinib for EGFR mutations and specialized interventions like NanoKnife or cryosurgery. JCI-accredited facilities in Guangzhou and Xiamen provide these high-tech protocols.
Bookimed Expert Insight: China's oncology landscape excels in combining interventional radiology with systemic drugs. Data shows clinics like Fuda Cancer Hospital serve over 30,000 patients using `3C` therapy. This combines cryosurgery, cancer microvascular intervention, and combined immunotherapy. While many countries focus solely on drugs, Chinese protocols often integrate physical tumor destruction for advanced cases.
Patient Consensus: Patients emphasize the need for broad genomic testing to match mutations with the right drug. Many note that outcomes improve significantly when seeking care at major thoracic oncology centers in cities like Guangzhou.
Leading Chinese hospitals for advanced-stage lung cancer include JCI-accredited hubs and specialized oncology centers in Guangzhou and Xiamen. These facilities focus on molecular profiling, cryosurgery, and microwave ablation. They provide alternatives for patients who cannot tolerate traditional systemic chemotherapy or standard surgery.
Bookimed Expert Insight: While many seek big-name public centers, specialized private hospitals in Guangzhou often provide faster access to interventional treatments. Dr. Liuying at Jinshazhou Hospital specifically contributed to national expert consensus on lung tumor ablation. These specialists focus on local tumor destruction when systemic resistance develops after initial targeted therapies.
Patient Consensus: Patients emphasize finding centers that perform rapid molecular testing and immediate biopsy reviews. Many note that traveling to major cities for initial staging is crucial to confirm genetic mutations correctly.
International patients can legally join clinical trials for lung cancer in China. Most opportunities exist within Multi-Regional Clinical Trials (MRCTs) or specific protocols without ethnic restrictions. Participation requires meeting strict biomarker profiles. Patients must also manage complex Chinese-language legal documentation and long-term residency visas.
Bookimed Expert Insight: Clinical trial enrollment is distinct from private-pay treatment at JCI-accredited centers. Clinicians like Dr. Liuying at Jinshazhou Hospital participate in provincial research projects. However, these academic studies may have stricter age limits than Western trials. Choose high-volume centers like Fuda Cancer Hospital, which has treated patients from 100+ countries, to ensure better logistical support.
Patient Consensus: Patients note trial screening takes time while Stage 4 cancer progresses fast. They emphasize getting full biomarker testing before traveling and having a standard treatment backup plan.
Traditional Chinese Medicine (TCM) serves as a supportive therapy for stage 4 lung cancer. It integrates with Western protocols like chemotherapy and immunotherapy. The approach aims to reduce treatment toxicity. Specialists focus on boosting immunity and protecting organ function during advanced oncology care.
Bookimed Expert Insight: Clinical integration in China often features specialized leadership. At the Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Dr. Liuying leads an oncology ward while holding credentials in both Chinese medicine and advanced thermal ablation. This dual expertise allows for precise timing of TCM therapies to support interventions like microwave or cryoablation without compromising the primary cancer treatment.
Patient Consensus: Patients note that TCM is highly effective for regaining appetite and managing the heavy exhaustion between chemotherapy cycles. Most emphasize that sharing all herbal ingredients with their primary oncologist is vital to avoid drug interactions.
Fitness for travel to China depends on respiratory stability and official oncology clearance. Long-haul flights pose risks like hypoxia and deep vein thrombosis for stage 4 patients. Specialized centers in Guangzhou offer minimally invasive alternatives to chemotherapy. These facilities are Joint Commission International accredited for safety.
Bookimed Expert Insight: China's top oncology centers like Fuda Hospital treat 30,000+ international patients with specific minimally invasive technologies. Our data shows these facilities often accept late-stage cases that others may decline. They use over 10 different thermal ablation techniques to target tumors without traditional major surgery. This specialized focus on advanced stages makes them a frequent choice for palliative or complex care.
Patient Consensus: Patients emphasize the need to stabilize symptoms like pain or pleural effusions before flying. They also recommend arranging portable oxygen and ground logistics before departing.
China follows CSCO guidelines which largely mirror Western NCCN and ESMO standards for stage 4 lung cancer. Protocols prioritize biomarker-driven targeted therapy and immunotherapy. Chinese centers show higher EGFR mutation rates, directing focus toward specific tyrosine kinase inhibitors and aggressive combination regimens.
Bookimed Expert Insight: Data from top-tier facilities like Fuda Cancer Hospital shows a distinct focus on combining systemic drugs with advanced local interventions. While Western protocols often stay systemic for stage 4, Chinese specialists frequently integrate microwave ablation or cryosurgery for metastases. This aggressive local-regional approach aims to reduce tumor burden alongside standard chemotherapy or immunotherapy.
Patient Consensus: Patients note that receiving international-standard care depends on choosing major urban hospitals with broad molecular testing. They emphasize getting all mutation data in writing to ensure treatments match specific cancer subtypes.